These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22202100)

  • 21. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
    Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
    Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current perspectives in prostate cancer vaccines.
    Arlen PM; Gulley JL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
    Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
    Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccines for the treatment of prostate cancer.
    Alam S; McNeel DG
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on prostate cancer vaccines.
    Drake CG
    Cancer J; 2011; 17(5):294-9. PubMed ID: 21952278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
    Fensterle J; Bergmann B; Yone CL; Hotz C; Meyer SR; Spreng S; Goebel W; Rapp UR; Gentschev I
    Cancer Gene Ther; 2008 Feb; 15(2):85-93. PubMed ID: 18084243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.
    Slovin SF
    Clin Prostate Cancer; 2005 Sep; 4(2):118-23. PubMed ID: 16197613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
    Mai TJ; Ma R; Li Z; Bi SC
    Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.
    Simms MS; Scholfield DP; Jacobs E; Michaeli D; Broome P; Humphreys JE; Bishop MC
    Br J Cancer; 2000 Aug; 83(4):443-6. PubMed ID: 10945488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
    Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
    Urology; 1999 Feb; 53(2):260-6. PubMed ID: 9933036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
    Miller AM; Ozenci V; Kiessling R; Pisa P
    J Immunother; 2005; 28(4):389-95. PubMed ID: 16000958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
    Rojan A; Funches R; Regan MM; Gulley JL; Bubley GJ
    Clin Genitourin Cancer; 2013 Sep; 11(3):362-4. PubMed ID: 23791437
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
    Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
    Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
    Karan D
    Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.